Si Belle PLLA+ 400 or 380
Si Belle PLLA+ — 380 mg and 400 mg Models
The Si Belle PLLA portfolio includes two formulations with different compositions, particle specifications and preparation instructions. This page presents both models in full so that their specifications can be compared directly.
Model comparison
Si Belle PLLA380+: 380 mg per vial: PLLA 200 mg, high-molecular-weight HA 40 mg, low-molecular-weight HA 40 mg and mannitol 100 mg. Microspheres: 10–60 µm. Stated hydration time: 3 hours.
Si Belle PLLA+ 400 / PL-400: 400 mg per vial: PLLA 340 mg and HA 60 mg. Microspheres: approximately 30 µm. Stated hydration time: 15–30 minutes.
Si Belle PLLA380+ — Product overview
Si Belle PLLA380+ combines 200 mg poly-L-lactic acid (PLLA), 40 mg high-molecular-weight hyaluronic acid, 40 mg low-molecular-weight hyaluronic acid and 100 mg mannitol in a 380 mg vial. The product information describes facial volume loss, wrinkles and contour concerns, and explains a progressive process involving PLLA microspheres, tissue response and collagen formation.
380 mg model: A four-ingredient formulation
Each vial contains PLLA 200 mg, H-HA 40 mg, L-HA 40 mg and mannitol 100 mg, for a total content of 380 mg.
The formulation combines PLLA microspheres with hyaluronic acid. PLLA-related tissue response is part of the manufacturer’s formulation rationale.
Poly-L-lactic acid (PLLA): Amount per vial: 200 mg; Share stated in the catalogue: 52.6%
Hyaluronic acid: H-HA 40 mg + L-HA 40 mg: Amount per vial: 80 mg total; Share stated in the catalogue: 21.1%
Mannitol: Amount per vial: 100 mg; Share stated in the catalogue: 26.3%
Total: Amount per vial: 380 mg; Share stated in the catalogue: 100%
380 mg model: PLLA material and microspheres
PLLA is poly-L-lactic acid, a polymer formed from L-lactic acid units. The supplied catalogue discusses biodegradation and the biological response around PLLA particles.
The product has a stated microsphere particle range of 10-60 µm. PLLA and HA are biodegradable materials.
380 mg model: Role and principle
The manufacturer describes a progressive process involving PLLA microspheres, tissue response and collagen formation.
1. PLLA microspheres: Microspheres are introduced into the treatment area.
2. Tissue response: The proposed process involves cell migration around the particles.
3. Collagen formation: The manufacturer links this tissue response with collagen formation.
380 mg model: Facial areas and treatment planning
The product information describes facial volume loss, wrinkles and contour concerns. Area selection and suitability are assessed by the treating clinician.
Forehead
Cheekbones
Cheeks
Nasolabial folds
Chin
380 mg model: Professional preparation: 380 mg model
Preparation, treatment and follow-up are planned by the treating clinician for the individual patient. The following technical parameters are reproduced from the 380 mg model information.
Vial content: 380 mg
Water for injection: 9.5 mL
Lidocaine: 2.5 mL of 2% lidocaine
Hydration time: 3 hours
Vortex mixing: 1-2 minutes at the beginning and end
380 mg model: Treatment schedule and reported duration
The manufacturer describes 2-3 sessions, approximately 4 weeks apart. The treating clinician determines the individual treatment plan.
The manufacturer cites an effect of approximately 18-24 months after an initial 2-3 sessions. This is a reported estimate; individual durability varies.
380 mg model: Aftercare and follow-up
Discuss swelling, skin changes and follow-up timing with your treating clinician.
Massage, cooling and other home-care measures should follow the treating clinician’s individual instructions.
Pain, bruising, injection marks and swelling may occur. Recovery and return to activities depend on the individual clinical response.
Nodules can occur and may require further treatment. The treating clinician assesses and manages individual concerns.
The manufacturer attributes some early volume to the preparation fluid. Swelling and appearance can change as that fluid is absorbed.
380 mg model: Manufacturer application examples
The supplied brochure includes two nasolabial-region photograph sets: before and after 2 months; before and after 3 months.
Explore the complete PLLA380+ product guide
Si Belle PLLA+ 400 — Product overview
Si Belle PLLA+ 400 combines 340 mg poly-L-lactic acid (PLLA) and 60 mg hyaluronic acid (HA) in a 400 mg vial. The PL-400 model is a two-component formulation containing 85% PLLA and 15% HA, with approximately 30 µm microspheres and a stated hydration time of 15-30 minutes.
400 mg model: A two-component formulation
The PL-400 table lists 340 mg PLLA and 60 mg HA per vial. These quantities total 400 mg; the visible Si Belle pack lists the same component amounts.
The formula contains 85% PLLA and 15% HA by weight.
Poly-L-lactic acid (PLLA): Amount per vial: 340 mg; Share: 85%
Hyaluronic acid (HA): Amount per vial: 60 mg; Share: 15%
Total: Amount per vial: 400 mg; Share: 100%
400 mg model: PLLA material and formulation principle
PLLA is poly-L-lactic acid, a polymer formed from L-lactic acid units.
The supplied catalogue presents a general PLLA rationale linking tissue response, collagen formation and material degradation.
400 mg model: PL-400 technical specifications
Product model: PL-400
PLLA contents: PLLA 340 mg + HA 60 mg
Package: 400 mg / vial
Particle size: Approximately 30 µm (microsphere)
Needle: 27G
Infusion volume (0.9% NaCl saline): 6 mL
Hydration time: 15-30 minutes
pH: 4.0-7.0
Osmotic pressure: 250-350 mOsm/kg
Normal force (N): 0.9-2.0 N
400 mg model: Professional preparation overview
The PL-400 preparation table lists 6 mL of 0.9% normal saline plus 2 mL lidocaine, for a total preparation volume of 8 mL.
0.9% normal saline: 6 mL
Lidocaine: 2 mL
Total: 8 mL
1. Aluminium cap: Remove the aluminium cap from the vial.
2. Alcohol swab: Clean with an alcohol swab.
3. Saline transfer: An 18G needle and 10 mL syringe are shown for drawing up saline.
4. Powder mixing: Syringe mixing is shown; a vortex mixer is also mentioned.
5. Suspension mixing: Gentle vial agitation is shown.
6. Lidocaine addition: The PL-400 table specifies 2 mL. The general source illustration states 1-2 cc.
7. Syringe transfer: Transfer to a 1-10 mL syringe, as shown in the source.
8. Blunt cannula: The source preparation illustration lists 26-30G and deep dermal/subcutaneous layers.
400 mg model: Self-care for better results
The brochure describes two post-treatment care measures: cold-pack care and the 7-3-3 massage rule.
Cold-pack care: within 24 hours after the procedure, the source advises an ice pack to reduce swelling.
7-3-3 rule: massage for 3 minutes, 3 times a day, for 7 days.
400 mg model: Before and after examples in the catalogue
The catalogue includes eight photograph sets across four pages.
Two facial sets show the labels Before, After 1 day, After 1 month and After 3 month.
The remaining sets show before/after views of facial contour, the buttock region, the eye area and the nasolabial region. No treatment interval is printed for these sets.
Keep the two model instructions together with the correct formulation
The 380 mg preparation uses 9.5 mL water for injection and 2.5 mL of 2% lidocaine, with a stated hydration time of 3 hours. The PL-400 preparation table uses 6 mL of 0.9% normal saline and 2 mL lidocaine, with a stated hydration time of 15–30 minutes. The 2–3 session schedule and the reported 18–24 month duration belong to the 380 mg product information.
Explore the complete PLLA+ 400 product guide
